Caspian Therapeutics launches with $50M to repurpose menin inhibitors for diabetes

Caspian Therapeutics launched with $50M to develop menin inhibitors for diabetes and cardiometabolic diseases, based on leukemia drug data suggesting a novel mechanism. The approach is early-stage and unproven in metabolic disease, but if validated could open a new therapeutic avenue. The financing signals investor interest in repurposing oncology targets for metabolic indications.